10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS www.virology-education.com

INTRODUCTION Please find herewith our sponsorship request for the fourth edition of the Workshop on HCV Therapy Advances New Antivirals in, scheduled to take place on 4 and 5 December 2015 in Amsterdam, the Netherlands. The landscape of clinical management of Hepatitis infection is evolving quickly; a second wave of new drugs is on the horizon and our clinical experience with the first approved Protease inhibitor in real life increases day by day. It is crucial that the Hepatitis-treating community is educated in order to be able to provide optimal clinical care to their Hepatitis infected patients. Our meeting aims to meet this important educational need. The timing of the meeting just after AASLD and the collaboration with international Key Opinion Leaders makes this an unique meeting in which the most important data presented at EASL, APASL and AASLD can be shared, discussed and translated to daily clinical care. We have set up a program for treating physicians to discuss the latest developments in the field of Hepatitis C treatment and the promising treatment possibilities of new antivirals that are becoming available. The conference presentations will focus on the translation of these new data and availability of new drugs into daily clinical practice. In addition, case discussions are an important part of this conference. With this sponsorship request we would like to invite you to support the organization of this important educational program. In order to be able to deliver this event we depend on your contribution. We would like to encourage you to help us organize this important conference and to demonstrate your commitment to this field. This meeting prospectus is designed in order to provide information on the meeting setup, demographics and metrics and also on the evaluation scores from the 2014 workshop participants. We hope this information is of interest. Please contact us if you would like to receive further information on a specific topic. We hope you will join us in this important initiative. Kind regards, The Program Committee of 2015 STEFAN ZEUZEM, MD J.W. Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute/ University of Texas Health Science Center Texas, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center Rotterdam, the Netherlands MEETING PROSPECTUS 5 th HCV Theraphy Advances - 2

WORKSHOP DESCRIPTION BACKGROUND The entrance of HCV direct acting antivirals into routine clinical practices provides a great opportunity for improved care, but at the same time, substantial challenges for the treating physician. The Workshop on HCV Therapy Advances has been developed to educate treating physicians and researchers, to discuss the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals. The conference presentations and case discussions presented by international recognized experts in the field are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. MEETING OBJECTIVES The objective of this meeting is to create an interactive setting in which key opinion leaders present and discuss the latest scientific data on clinical management of hepatitis infected patients. FORMAT This 1,5 day international workshop consists of invited lectures and panel debates in which sufficient time is allocated for interactive discussion between the panel and the audience. UNIQUE MEETING FEATURES The workshop is a unique European platform for clinicians and other professionals working in the field of viral hepatitis, translating new data into new treatment strategies to further improve clinical care The workshop attracts different disciplines involved in the field of HCV therapy The workshop includes the latest data presented at EASL, APASL and AASLD The workshop stimulates European collaborations and networks The workshop stimulates updates on guidelines and encourages treatment efficiency TARGET AUDIENCE Hepatologists Infectious disease doctors Gastroenterologists Other healthcare professionals involved in daily care of hepatitis patients Post-graduate students MEETING PROSPECTUS 5 th HCV Theraphy Advances - 3

WORKSHOP DESCRIPTION LEARNING OBJECTIVES Have an understanding of the basic concepts of HCV therapy. Be updated on the latest developments in the field of HCV antiviral research. Have an understanding of the challenges of HCV treatment in different patient populations. Have an overview of the advantages and possibilities of Have an understanding of the basic concepts of HCV therapy. Be updated on the latest developments in the field of HCV antiviral research. Have an understanding of the challenges of HCV treatment in different patient populations. Have an overview of the advantages and possibilities of new antivirals in HCV therapy. Know how to apply direct acting antivirals in clinical practice. MEETING PROSPECTUS 5 th HCV Theraphy Advances - 4

ORGANIZING COMMITTEE CHARLES BOUCHER, MD, PHD Erasmus Medical Center Rotterdam, the Netherlands FRED POORDAD, MD Texas Liver Institute/ University of Texas Health Science Center Texas, USA STEFAN ZEUZEM, MD J.W. Goethe University Hospital Frankfurt, Germany MEETING PROSPECTUS 5th HCV Theraphy Advances - 5

MEETING DEMOGRAPHICS NUMBER OF PARTICIPANTS A growth of attendance numbers was seen in 2014. 110 delegates from 20 countries participated in the event. The largest group was from France (35). 86% of the participants indicated themselves as first time participants and 14% are returning participants. The geographical distribution of participants is as follows: Country Delegates Country Delegates Canada 2 the Netherlands 4 Denmark 3 Norway 1 Egypt 3 Poland 8 Finland 3 Portugal 1 France 35 Romania 2 Germany 2 Spain 3 Greece 1 Sweden 14 Israel 2 Turkey 1 Italy 2 United Kingdom 11 Lithuania 11 USA 4 PROFESSIONAL BACKGROUND Main activity: Mainly employed by: Nurse 13% Community rep 10% Other Other 15% University Clinician 22% 30% 34% Researcher 28% Industry marketing 13% Industry medical 12% Hospital 23% Area of expertise: Other 17% Hepatitis B 32% Hepatitis C 51% MEETING PROSPECTUS 5 th HCV Theraphy Advances - 6

PARTICIPANTS FEEDBACK 2014 FRIDAY 12 DECEMBER 2014, DAY 1 PERSONAL BENEFITS The content presented of this workshop day will improve my: Very much agree Agree Neutral Disagree Very much disagree Medical and/or Practical Knowledge 49% 34% 14% 0% 3% Care Attitudes 37% 30% 26% 7% 0% Procedural or Cognitive Skills 27% 27% 35% 8% 4% Practice Behavior 31% 31% 35% 4% 0% Patients Clinical Outcomes 31% 38% 27% 4% 0% CONTENT Agree Disagree Disagree The content of this day s program met my expectations 94% 3% 3% Sufficient time was allocated for discussion 83% 14% 3% The allocated time per presentation was sufficient 76% 12% 12% I perceived no commercial bias at this workshop day 90% LECTURES Session 1 Presented Data 2014 Pivotal New England Journal of Medicine Papers 2014 Phase 3 Trial Data S. Zeuzem, MD News from AASLD Nuke Regimens F. Poordad, MD News from AASLD Non Nuke Regimens M. Buti, MD, PhD Content 56% 37% 7% 0% 0% Presentation 58% 38% 4% 0% 0% Content 71% 24% 5% 0% 0% Presentation 68% 28% 4% 0% 0% Content 46% 39% 10% 5% 0% Presentation 40% 35% 13% 12% 0% MEETING PROSPECTUS 5 th HCV Theraphy Advances - 7

PARTICIPANTS FEEDBACK 2014 GILEAD - Satellite Symposium Presentations Content 63% 31% 6% 0% 0% Presentation 59% 35% 6% 0% 0% I will change my daily practice as a result of attending this Satellite Symposium Very much Agree Neutral Disagree Very much agree disagree 34% 29% 29% 4% 4% Session 2 Differential Benefits of DAA s in Different Patient Populations In Patients on a Waiting List for Liver Transplantation Content 36% 53% 11% 0% 0% The Data - R. Brown, MD, PhD Presentation 39% 50% 11% 0% 0% The Clinic - R. de Knegt, MD, PhD Presentation 49% 43% 8% 0% 0% In HIV - HCV Coinfected Patients Content 44% 33% 19% 3% 0% The Data - K. Lacombe, MD, PhD Presentation 39% 32% 24% 5% 0% The Clinic - S. Pol, MD, PhD Presentation 39% 32% 24% 5% 0% In HIV - HCV Coinfected Patients Content 65% 25% 10% 0% 0% The Data - G. Dusheiko, MD Presentation 60% 25% 10% 5% 0% The Clinic - M. Bourlière, MD Presentation 55% 30% 10% 5% 0% MEETING PROSPECTUS 5 th HCV Theraphy Advances - 8

PARTICIPANTS FEEDBACK 2014 SATURDAY 13 DECEMBER, DAY 2 PERSONAL BENEFITS The content presented at this workshop day will improve my: Very much agree Agree Neutral Disagree Very much disagree Medical and/or Practical Knowledge 64% 29% 7% 0% 0% Care Attitudes 43% 36% 18% 4% 0% Procedural or Cognitive Skills 44% 40% 12% 4% 0% Practice Behavior 32% 48% 16% 4% 0% Patients Clinical Outcomes 44% 40% 16% 0% 0% CONTENT Agree Neutral Disagree The content of the meeting met my expectations 94% 6% 0% Sufficient time allocated for discussion during the meeting 97% 3% 0% The allocated time per presentation was sufficient 97% 0% 3% I perceived no commercial bias at this workshop day 88% LECTURES I gained new insights from the following invited lectures and discussions (in chronological order) Session 3 Next Steps 2015 and Beyond What is the Optimized Treatment Duration? To Over treat versus Undertreat N. Reau, MD Comparing the Different Guidelines (WHO/EASL/AASLD) F. Poordad, MD Content 57% 37% 6% 0% 0% Presentation 57% 40% 3% 0% 0% Content 60% 37% 3% 0% 0% Presentation 63% 37% 0% 0% 0% Panel Discussion Country Specific Consideration of the Guidelines Content 70% 30% 0% 0% 0% MEETING PROSPECTUS 5 th HCV Theraphy Advances - 9

PARTICIPANTS FEEDBACK 2014 ABBVIE - Satellite Symposium Presentations Content 52% 39% 9% 0% 0% Presentation 55% 35% 10% 0% 0% My daily practice will be enhanced after attending this Satellite Symposium Very much Agree Neutral Disagree Very much agree disagree 33% 50% 13% 4% 0% Session 4 Eradication What are the Critical Steps Needed for Global HCV Eradication H. Wedemeyer, MD Content 56% 41% 3% 0% 0% Presentation 62% 38% 0% 0% 0% MEETING PROSPECTUS 5 th HCV Theraphy Advances - 10

PARTICIPANTS FEEDBACK 2014 GENERAL LEARNING OBJECTIVES Were the following learning objectives met? After attending this event, the participant will demonstrate the ability to: Agree Neutral Disagree Have insight in the various aspects of the different drug classes affecting the regimen choice 90% 7% 3% Understand the efficacy and safety differences between nucleoside agents in HCV 84% 13% 3% Is aware of the similarities and differences in various HCV guidelines 94% 6% 0% Have knowledge on the patient populations appropriate for shorter duration therapy Understand the impact on SVR of shorter duration therapy by treatment regimen Understand the current and upcoming treatment options for hepatitis C in advanced disease and liver transplantation Have knowledge on the potential drug drug interaction in co-infected patients 97% 3% 0% 97% 3% 0% 86% 13% 0% 70% 27% 3% NEXT YEAR I will change my daily practice after attending this workshop 67% I plan to attend this workshop again next year 91% AVERAGE SCORES PARTICIPANTS FEEDBACK Percentage of scores scored Excellent/Good Content Presentation Invited speakers 91% 89% Debates 100% - MEETING PROSPECTUS 5 th HCV Theraphy Advances - 11

PARTICIPANTS FEEDBACK LOGISTICS Location was suitable for this meeting 63% 33% 4% 0% 0% Location was easy to reach 60% 35% 5% 0% 0% Food & beverages were good and sufficient 56% 26% 13% 5% 0% Audio-visual equipment was good and sufficient 48% 38% 14% 0% 0% On-site staff was professional and helpful 55% 43% 3% 0% 0% COMMUNICATION The information received through the newsletters was sufficient The information received through the logistical letter was useful I perceived the information at the Virology Education website as useful 33% 59% 4% 4% 0% 34% 58% 8% 0% 0% 46% 50% 4% 0% 0% PUBLICITY Influenced to attend this meeting by: Colleague / word of mouth 45% VE email announcement 34% Invite from industry 14% VE website 3% Other conference agenda 2% Internet search 2% MEETING PROSPECTUS 5 th HCV Theraphy Advances - 12

METRICS 2014 PRE-WORKSHOP COMMUNICATION Frequency/Number Publicity through electronic newsletter Flyers at other meetings Endorsement by societies Publicity on conference websites Invitations from industry Publicity through associations and other organizations 5 electronic newsletters have been sent to an international group of 4.552 recipients. 1 electronic newsletter has been dedicated to attract Dutch participants. The meeting flyer has been distributed at the EASL The Liver Meeting 2014 and at AASLD 2014. The meeting is endorsed by Société Francaise de Lutte Contre Le SIDA (SFLS) and ANRS The website has been promoted at multiple international meeting websites. Participants to the meeting were brought by Gilead, AbbVie, BMS and Roche The meeting has been promoted on the websites of the endorsing societies. POST-WORKSHOP COMMUNICATION Webcast/On-line education Publication of presentation slides online Post Conference Newsletter A webcast of the invited lectures has been made available online for educational purposes at http:// www.infectiousdiseasesonline.com/4th-hcvtherapy-adv-webcasts. The slides of the presentations have been made available online at http://www. infectiousdiseasesonline.com/4th-hcv-therapy-advpresentations. A Post Conference Newsletter with a link to the webcast and presentation slides has been sent to the participants of this and previous years workshops. MEETING PROSPECTUS 5 th HCV Theraphy Advances - 13

SUMMARY AND CONTACT DETAILS The Program Committee is pleased with the excellent results of the 4 th Workshop on HCV Therapy Advances. Participants were satisfied with the scientific content of the workshop as well as with the logistics and the format of the meeting. The program provided an excellent format including, invited speakers and panel debates and the Program Committee looks forward to organizing the 5 th edition of the workshop in December 2015 in Amsterdam, the Netherlands. We hope the information in this meeting prospectus is of interest to you. Please contact us if you would like to receive further information on a specific topic. We look forward to working with you on this exciting program! On behalf of the Virology Education Team, Alice Postumus - Plantinga Managing Director CONTACT DETAILS Virology Education Biltstraat 106 3572 BJ Utrecht T: +31 (0) 30 230 71 40 M: +31 (0) 6 2248 2179 E: alice.posthumus-plantinga@vironet.com MEETING PROSPECTUS 5 th HCV Theraphy Advances - 14